Indeed, several clinical trials have pointed out the variability in efficacy of trastuzumab-containing regimens depending on ER and HER2 status of the tumours, suggesting heterogeneous biological characteristics8, 9, 10, 11. This evidence concerns the gene ESR1 and neoplasm.